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OBJECTIVE—Some obese youth with a clinical diagnosis of
type 2 diabetes have evidence of islet cell autoimmunity with
positive autoantibodies. In this study, we investigated the differ-
ences in insulin sensitivity and secretion between autoantibody-
negative (Ab
) and -positive (Ab
) youth with clinically
diagnosed type 2 diabetes in comparison with control subjects.
RESEARCH DESIGN AND METHODS—Sixteen Ab
 and 26
Ab
 clinically diagnosed type 2 diabetic patients and 39 obese
control youth underwent evaluation of insulin sensitivity (3-h
hyperinsulinemic-euglycemic clamp), substrate oxidation (indi-
rect calorimetry), ﬁrst- and second-phase insulin secretion (2-h
hyperglycemic clamp), body composition and abdominal adipos-
ity (dual energy X-ray absorptiometry and computed tomography
scan, respectively), and glucose disposition index (ﬁrst-phase
insulin secretion  insulin sensitivity).
RESULTS—Insulin-stimulated total, oxidative, and nonoxida-
tive glucose disposal, and suppression of fat oxidation during
hyperinsulinemia were signiﬁcantly lower in Ab
 compared with
Ab
 clinically diagnosed type 2 diabetic and control subjects
with no difference between the latter two. First- and second-
phase insulin secretion and C-peptide were lower in Ab
 com-
pared with Ab
 type 2 diabetes. Glucose disposition index was
not different between the Ab
 and Ab
 clinically diagnosed type
2 diabetic patients, but both were signiﬁcantly lower than that in
control subjects. Systolic blood pressure and alanine aminotrans-
ferase were higher in Ab
 versus Ab
 clinically diagnosed type 2
diabetic patients, whereas the frequency of ketonuria at diagno-
sis was higher in Ab
 versus Ab
 patients.
CONCLUSIONS—Islet-cell Ab
 clinically diagnosed type 2 dia-
betic youth are characterized by severe insulin resistance and
relative insulin deﬁciency, whereas Ab
 youth have severe
insulin deﬁciency and -cell failure. The former group has
additional features of insulin resistance. These important meta-
bolic differences could inﬂuence the natural history of hyper-
glycemia, insulin dependence, and clinical outcomes in these
youth. Diabetes 58:738–744, 2009
T
he clinical presentation of type 2 diabetes in
youth is diverse, from minimal symptomatology
to severe clinical manifestations with evidence
of hyperglycemia with or without ketosis (1).
Diabetes in humans is classiﬁed into two main types: type
1 diabetes, where the pathophysiology is autoimmune
destruction of the pancreatic -cells; and type 2 diabetes,
where insulin resistance is central to the disease process
together with a nonimmune-mediated -cell failure rela-
tive to insulin resistance (2). Limited data in the pediatric
literature suggest that the pathophysiology of youth type 2
diabetes is a combination of severe insulin resistance and
relative insulin deﬁciency (3–6).
The diagnosis of youth type 2 diabetes is typically made
using clinical criteria where obesity is the major diagnostic
entity (7). However, with the increasing rates of obesity in
childhood, particularly in children with type 1 diabetes,
this clinical distinction has become ever more difﬁcult and
imperfect (8,9). A number of youth with a clinical diagno-
sis of type 2 diabetes have evidence of islet-cell autoim-
munity, with autoantibodies present in 10–75% of patients
(10–15). Several theories and terminologies have been
proposed, such as hybrid diabetes, double diabetes, dia-
betes type 1.5, and latent autoimmune diabetes of youth,
to refer to and to try to explain the underlying pathophys-
iology in this subset of young patients with a clinical
phenotype consistent with type 2 diabetes and evidence of
autoimmunity consistent with type 1 diabetes (8,13,15–18).
Efforts to identify distinguishing features of antibody-
positive (Ab
) and -negative (Ab
) clinically diagnosed
type 2 diabetes in youth, which are typically focused on
clinical features such as obesity, acanthosis nigricans,
symptoms at diagnosis, ketonuria, A1C, and insulin re-
quirements, have not revealed any unique distinctive fea-
tures that would differentiate one from the other
(10,12,15). To our knowledge, no data exist in the pediatric
literature regarding the metabolic characteristics of youth
with a clinical diagnosis of type 2 diabetes with versus
without islet cell antibodies. Therefore, the aim of the
present investigation was to test the hypothesis that youth
with clinically diagnosed type 2 diabetes and positive islet
cell antibodies have greater impairment of -cell function
and are less insulin resistant than their peers with clini-
cally diagnosed type 2 diabetes who are autoantibody
negative. Our objectives were 1) to compare in vivo insulin
sensitivity and secretion in Ab
 versus Ab
 youth with
clinically diagnosed type 2 diabetes and in obese control
subjects and 2) to assess whether differences exist be-
tween the two groups of clinically diagnosed type 2 diabetic
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738 DIABETES, VOL. 58, MARCH 2009patients in clinical and/or laboratory features at the time of
diagnosis or during the research evaluation.
RESEARCH DESIGN AND METHODS
Study population. Forty-two obese adolescents with a clinical diagnoses of
type 2 diabetes made by the attending endocrinologist were recruited from the
Diabetes Center at Children’s Hospital of Pittsburgh. Screening for islet cell
antibodies (details below) revealed 16 with negative antibodies and 26 with
positive antibodies. Some of the Ab
 patients were initially screened for the
Treatment Options of Type 2 Diabetes in Adolescents and Youth Trial
(TODAY) (Children’s Hospital of Pittsburgh is one of 15 participating centers
in TODAY) (19) and found to be ineligible because of the presence of islet cell
antibodies. Some of the Ab
 patients later participated in TODAY. The control
group consisted of 39 age-matched obese but otherwise healthy adolescents
who were recruited from the community through a local newspaper adver-
tisement and ﬂyers posted on bus routes and the medical campus. Thirteen of
the 42 subjects with type 2 diabetes and all of the obese control subjects were
reported previously (4,20). Pubertal development was assessed by physical
examination according to Tanner criteria (21). At the time of study participa-
tion, 9 subjects with clinically diagnosed type 2 diabetes were receiving
lifestyle modiﬁcation and no medications, 6 patients were on insulin alone, 13
were on metformin alone, and 14 were on insulin together with metformin
(Table 1). This type of therapy is typical of pediatric diabetes clinical practices
nationwide (22,23). Besides the type 2 diabetes treatment, none of the
participants were receiving any medication that may have impacted glucose
metabolism, and none of the females were on oral contraceptive pills at the
time of the study. The characteristics of the study population are summarized
in Table 1. All studies were approved by the institutional review board of the
University of Pittsburgh. Informed consent and assent were obtained from
each participant and their legal guardians. Clinical and laboratory character-
istics of type 2 diabetic youth at the time of diagnosis, including presence of
symptoms, ketones, glucose levels, A1C, and treatment modality and/or
insulin use at diagnosis were obtained from the medical records.
Autoantibody testing. Glutamic acid decarboxylase 65-kDa autoantibody
(GAD65-Ab) and insulinoma-associated protein-2 autoantibody (IA2 Ab) mea-
surements were performed at the Northwest Lipid Metabolism and Diabetes
Research Laboratories, University of Washington (Seattle, WA). This is the
same reference laboratory with identical antibody determination for the
National Institutes of Health (NIH)-funded multicenter TODAY study (19).
Brieﬂy, both GAD and IA2 were determined by a radioligand-binding assay,
using either GAD65 or IA2 proteins produced by an in vitro transcription and
translation system and labeled with [
35S]methionine. Levels of both GAD65-Ab
and IA2 Ab were expressed as indexes, with the cutoff for positivity set at the
99th percentile of normal. Subjects with GAD65-Ab index 0.085 and/or IA2
Ab index 0.018 were considered to be GAD65-Ab
 and/or IA2-Ab
, respec-
tively. Patients were considered to be Ab
 if both antibody indexes were
below the cutoff. These are the same cutoffs used in TODAY (19).
Clamp studies. Participants were admitted twice within a 1- to 4-week period
(except for three control subjects within 6–8 weeks) to the Pediatric Clinical
and Translational Research Center the day before the clamp studies: once for
a hyperinsulinemic-euglycemic clamp and once for a hyperglycemic clamp—
in random order. Each clamp evaluation was performed after a 10- to 12-h
overnight fast. Metformin and long-acting insulin were discontinued 48 h before
the clamp studies as reported previously (4). For each study, two intravenous
catheters were inserted after the skin and subcutaneous tissues were anesthe-
tized with eutectic mixture of local anesthetics cream (Astra Pharmaceutical
Products, West Borough, MA). One catheter was placed in a vein on the forearm
for administration of glucose, insulin, and stable isotopes; the second catheter
was placed in a vein in the dorsum of the contralateral heated hand for sampling
of arterialized venous blood (4).
In vivo glucose metabolism and insulin sensitivity. Fasting endogenous
hepatic glucose production (HGP) was measured with a primed (2.2 mol/kg)
constant rate infusion of [6,6-
2H2]glucose (0.31  0.01 mol  kg
1  min
1 in
type 2 diabetic patients and 0.30  0.01 mol  kg
1  min
1 in obese control
subjects) (Isotech, Miamisburg, OH) from 7:30–9:30 A.M., as we described
previously (4). Blood was sampled at the start of the stable isotope infusion
(120 min) and every 10 min from 30 to 0 min (basal period) for
determination of plasma glucose, insulin, and isotopic enrichment of glucose.
Calculations for fasting HGP were made over the last 30 min of the 2-h isotope
infusion (30 to 0 min).
After the 2-h baseline isotope infusion period, insulin-mediated glucose
metabolism and in vivo insulin sensitivity were measured during a 3-h
hyperinsulinemic-euglycemic clamp from 9:30 A.M.-12:30 P.M., in conjunction
with indirect calorimetry. Intravenous crystalline insulin (Humulin Regular;
Lilly, Indianapolis, IN) was infused at a constant rate of 80 mU  m
2  min
1,
and plasma glucose was clamped at 5.5 mmol/l with a variable rate infusion of
20% dextrose as before (4,20). Continuous indirect calorimetry by a ventilated
hood system (Deltatrac Metabolic Monitor; Sensormedics, Anaheim, CA) was
performed to measure CO2 production, O2 consumption, and respiratory
quotient for 30 min at baseline and at the end of the clamp (4).
In vivo insulin secretion. First- and second-phase insulin secretion were
assessed during a 2-h hyperglycemic clamp (12.5 mmol/l) performed from
9:00–11:00 A.M. as described previously (4). Glucose, insulin, and C-peptide
concentrations were measured every 2.5 min (at 2.5, 5, 7.5, 10, and 12.5 min,
ﬁrst phase) and then every 5 min for glucose and every 15 min for insulin and
TABLE 1
Characteristics of islet cell Ab
 and Ab
 obese youth clinically diagnosed with type 2 diabetes and obese control subjects
Clinically diagnosed type 2 diabetic patients
Obese control subjects
P value
Ab
 Ab
 ANOVA
Post
hoc
n 16 26 39
Age (years) 14.7  0.4 (10.1–17.2) 14.9  0.4 (10.2–18.3) 14.1  0.2 (12.3–17.2) NS NS
Sex (male/female) 7/9 11/15 23/16 NS
Ethnicity (African
American/Caucasian) 6/10 13/13 20/19 NS
Tanner stages
II-III 2 3 10 NS
IV-V 14 23 29
BMI (kg/m
2) 36.0  1.3 (28.3–45.4) 33.4  1.2 (24.5–48.9) 36.0  0.9 (28.0–49.6) NS NS
Body fat (%) 40.6  1.8 (24.9–48.4) 40.8  1.5 (22.6–52.9) 42.3  0.8 (32.1–51.1) NS NS
VAT (cm
2) 79.0  6.9 (47.1–142.8) 72.8  8.6 (26.5–242.4) 76.1  5.9 (16.7–161.4) NS NS
Subcutaneous adipose tissue
(cm
2) 520.1  40.7 (291.6–776.1) 491.5  29.8 (264.9–764.4) 556.1  23.9 (321.2–890.1) NS NS
Diabetes duration (months) 4.4  1.4 (0.05–18.0) 9.0  2.1 (1.0–39.0) NA NS
A1C (%) 6.8  0.2 (4.7–8.3) 6.5  0.2 (5.1–8.0) 5.3  0.1 (4.3–6.2) 0.001 NS
Treatment modality 	n (%)
 NA
Lifestyle modiﬁcation 4 (25) 5 (19.2) NS
Metformin 6 (37.5) 7 (26.9) NS
Insulin 2 (12.5) 4 (15.4) NS
Insulin and metformin 4 (25) 10 (38.5) NS
Data are means  SEM (range) or n (%). NA, not applicable. Post hoc P value, Bonferonni correction for Ab
 vs. Ab
 clinically diagnosed
type 2 diabetic patients. 
2 analyses with respect to ethnicity, sex, Tanner stage, and treatment modality.
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for total HDL, LDL, and VLDL cholesterol, triglycerides, alanine aminotrans-
ferase (ALT), and aspartate aminotransferase measurements.
Body composition. Body composition was determined by dual energy X-ray
absorptiometry. Subcutaneous abdominal adipose tissue and visceral adipose
tissue (VAT) were examined by a single-slice computed tomography (CT) scan
at L4-L5 as described previously (4,20).
Blood pressure determination. Blood pressure was measured when the
subjects were resting in the supine position in bed. Measurements were
performed with an automated sphygmomanometer every 10 min for 1 h
between 10:00 and 11:00 P.M. before the subject fell asleep and between 6:00
and 7:00 A.M. before awakening. The mean of seven measurements during each
hour was the outcome for statistical analysis (24).
Biochemical measurements. Plasma glucose was measured with a glucose
analyzer (Yellow Springs Instrument, Yellow Springs, OH), and insulin and
C-peptide were measured by radioimmunoassay as described previously
(4,25). A1C was measured by high performance liquid chromatography (1998;
Tosoh Medics) and lipids using the standards of the Centers for Disease
Control and Prevention (4,25). Deuterium enrichment of glucose in the plasma
was determined on a Hewlett-Packard 5973 mass spectrometer (Palo Alto,
CA) coupled to a 6890 gas chromatograph as reported previously (20).
Calculations. Fasting HGP was calculated during the last 30 min of the 2-h
isotope infusion according to steady-state tracer dilution equations (24,25).
Insulin-stimulated glucose disposal rate (Rd) was calculated during the last 30
min of the euglycemic clamp to be equal to the rate of exogenous glucose
infusion. Peripheral insulin sensitivity was calculated by dividing the Rd by the
steady-state clamp insulin level (24,25). Insulin-stimulated carbohydrate and
fat oxidation rates were calculated according to the formulas of Frayn (20,24)
from the indirect calorimetry data. Nonoxidative glucose disposal was esti-
mated by subtracting the rate of glucose oxidation from the total Rd. During
the hyperglycemic clamp, the ﬁrst- and second-phase insulin and C-peptide
concentrations were calculated as described previously (4,25). Glucose dis-
position index (GDI) was calculated as the product of insulin sensitivity 
ﬁrst-phase insulin.
Statistical analysis. Differences in continuous variables between Ab
 and
Ab
 clinically diagnosed type 2 diabetic and control subjects were tested with
either a one-way ANOVA or the nonparametric Kruskall-Wallis test, based on
the nonviolation of statistical assumptions. Differences in categorical vari-
ables were tested using the 
2 test or the Fisher’s exact test. All statistical
assumptions were met. Data are presented as mean  SE unless otherwise
indicated. Statistical signiﬁcance was set at P  0.05. All statistical analyses
were run using SPSS software (SPSS, Chicago).
RESULTS
Study participants. The clinical and physical character-
istics of the study participants are depicted in Table 1. The
three groups were comparable with respect to age, sex,
ethnicity, pubertal development, BMI, percent body fat,
and abdominal VAT and subcutaneous adipose tissue. As
expected, A1C was signiﬁcantly higher in clinically diag-
nosed type 2 diabetic patients compared with control
subjects but not different between Ab
 and Ab
 groups.
Similarly, duration of diabetes was not different between
Ab
 and Ab
 groups.
Fasting metabolic proﬁle. Fasting plasma glucose levels
were not signiﬁcantly different between Ab
 and Ab

groups but were signiﬁcantly higher than in obese control
subjects. Fasting insulin level was lowest and HGP was
highest in the Ab
 group (Table 2). Fasting lipids were not
signiﬁcantly different between Ab
 and Ab
 groups. Rates
of glucose and fat oxidation were not different between
the three groups. Baseline free fatty acids were higher in
the diabetic subjects compared with control subjects but
not different between Ab
 and Ab
 groups (Table 2).
In vivo insulin sensitivity. Steady-state plasma glucose
and insulin concentrations during the hyperinsulinemic-
euglycemic clamp were not different among the Ab
,A b
,
and obese control groups (5.6  0.03, 5.6  0.03, and 5.6 
0.02 mmol/l, respectively, and 1,677  113, 1,536  135,
and 1,758  73 pmol/l, respectively). Insulin-stimulated
total, oxidative, and nonoxidative glucose disposal was
signiﬁcantly lower in the Ab
 patients compared with their
Ab
 peers and obese control subjects, with no difference
between the Ab
 clinically diagnosed type 2 diabetic
patients and the obese control subjects (Fig. 1A). Insulin
sensitivity was lowest in the Ab
 patients versus Ab

versus control subjects (1.4  0.2, 2.5  0.3, and 2.0  1.1
mol  kg
1  min
1 per pmol/l, respectively, P  0.048).
Fat oxidation during the euglycemic clamp was signiﬁ-
cantly higher in Ab
 patients compared with Ab
 and
control subjects, with no difference between the latter two
groups (Fig. 1B). Percent suppression in fat oxidation
during the euglycemic clamp was signiﬁcantly lower in
Ab
 patients compared with Ab
 patients and control
subjects (26.4  0.1 in Ab
 vs. 55.5  6.6 in Ab
 and 50.8 
4.3% in control subjects, P  0.008) (Fig. 1C). Insulin-
stimulated glucose disposal (total, oxidative, and nonoxi-
dative) and insulin sensitivity remained signiﬁcantly lower
and fat oxidation remained signiﬁcantly higher in the Ab

patients compared with their Ab
 peers after adjusting for
race, A1C, and diabetes duration at the time of the clamp
studies.
In vivo -cell function during the hyperglycemic
clamp. First-phase insulin and C-peptide as well as sec-
ond-phase insulin and C-peptide levels were lowest in Ab

clinically diagnosed type 2 diabetic patients compared
TABLE 2
Fasting metabolic proﬁle of islet cell Ab
 and Ab
 obese youth clinically diagnosed with type 2 diabetes and obese control subjects
Clinically diagnosed type 2 diabetic patients
Obese control
subjects
P value
Ab
 Ab
 ANOVA
Post
hoc
n 16 26 39
Glucose (mmol/l) 6.6  0.4 (4.6–9.5) 7.4  0.4 (5.0–13.5) 5.4  0.1 (4.8–6.2) 0.001 NS
Insulin (pmol/l) 274  37 (77–690) 183  20 (49–472) 249  18 (95–573) 0.03 0.05
HGP (mol  kg
1  min
1) 13.3  0.6 (10.1–18.0) 16.1  1.1 (9.2–34.1) 13.1  0.5 (9.2–25.5) 0.02 NS
Glucose oxidation (mol  kg
1  min
1) 6.5  0.7 (3.8–11.4) 7.4  0.7 (2.5–17.8) 8.6  0.6 (3.1–16.1) 0.09 NS
Fat oxidation (mol  kg
1  min
1) 4.7  0.4 (2.2–7.8) 4.3  0.3 (1.4–7.5) 4.1  0.2 (2.1–8.8) NS NS
Free fatty acid baseline (mol/l) 439  23 (252–598) 427  24 (216–678) 341  18 (161–607) 0.003 NS
Cholesterol (mmol/l) 3.9  0.2 (2.5–5.0) 3.9  0.1 (2.9–5.6) 4.4  0.9 (2.3–6.6) 0.03 NS
HDL (mmol/l) 0.96  0.04 (0.65–1.33) 0.99  0.04 (0.67–1.69) 1.06  0.03 (0.70–1.53) NS NS
LDL (mmol/l) 2.3  0.2 (1.3–3.1) 2.4  0.1 (1.4–4.3) 2.7  0.1 (1.1–4.5) 0.04 NS
Triglycerides (mmol/l) 1.5  0.2 (0.6–3.9) 1.3  0.1 (0.6–3.4) 1.3  0.1 (0.6–4.3) NS NS
VLDL (mmol/l) 0.31  0.04 (0.11–0.79) 0.26  0.03 (0.11–0.67) 0.28  0.03 (0.11–0.86) NS NS
Data are means  SEM (range). Post hoc P value, Bonferonni correction for Ab
 vs. Ab
 clinically diagnosed type 2 diabetic patients.
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glycemia (ﬁrst-phase glucose, 12.6  0.1, 12.3  0.1, and
12.2  0.1 mmol/l; second-phase glucose, 12.7  0.0,
12.7  0.1, and 12.4  0.0 mmol/l, respectively). All of
these parameters of in vivo -cell function remained
signiﬁcantly lower in Ab
 clinically diagnosed type 2
diabetic patients compared with their Ab
 peers after
adjusting for race, A1C, and diabetes duration at the time
of the clamp studies. -Cell function relative to insulin
sensitivity, i.e., the glucose disposition index (GDI) did not
differ between the Ab
 and the Ab
 clinically diagnosed
type 2 diabetic patients but were signiﬁcantly lower than
obese control subjects (Fig. 2C).
Clinical and biochemical characteristics of Ab
 and
Ab
 clinically diagnosed type 2 diabetic youth. At the
time of diagnosis, there were no differences between Ab

and Ab
 clinically diagnosed type 2 diabetic youth in A1C
(10.1  0.8 and 10.8  0.6%, respectively; P  0.4), glucose
(15.4  2.3 and 19.9  1.2 mmol/l, P  0.13), presence of
symptoms, polyuria, polydypsia, or weight loss by patient
report, and family history of diabetes. However, ketonuria
was more frequent in Ab
 patients (57.7 vs. 18.8%, P 
0.01). Initiation of insulin treatment at diagnosis was
comparable between the two groups (62.5% in Ab
 vs.
73.1% in Ab
 patients, P  0.51), whereas initiation of
metformin therapy was more frequent among the Ab

patients (75% in Ab
 vs. 34.6% in Ab
, P  0.03). Four
subjects (two Ab
 and two Ab
) were started on lifestyle
modiﬁcation only and no medication (12.5% Ab
 vs. 7.6%
Ab
, P  0.63). Ten of the 29 patients who were started on
insulin treatment at diagnosis (four Ab
 and six Ab
)
became insulin free by the time of the clamp studies
(34.5%).
At the time of research evaluation, there were no
differences between Ab
 and Ab
 clinically diagnosed
type 2 diabetic patients in A1C, insulin use, and/or treat-
ment modalities (Table 1). However, nighttime systolic
blood pressure (121.9  2.5 vs. 113.0  1.8 mmHg,
respectively; P  0.006) and fasting ALT (40.5  5.0 and
28.4  1.7 units/l, P  0.03) were signiﬁcantly higher in the
Ab
 compared with Ab
 patients. The differences in
nighttime systolic blood pressure remained signiﬁcant
after adjusting for race, VAT, and insulin sensitivity (P 
0.011). A1C correlated with GDI (Fig. 3) but not with
insulin sensitivity or insulin secretion. In a multiple regres-
sion analysis with A1C as the dependent variable and GDI,
age, and VAT as the independent variables (r
2  0.612, P 
0.001), all three contributed signiﬁcantly (partial correla-
tions, GDI 0.71, P  0.001; age 0.52, P  0.001; VAT
0.42, P  0.013) and independently to explain 78% of the
variance in A1C.
Double Ab
 (2Ab
) versus single (1Ab
) positive.
Among the 26 Ab
 clinically diagnosed type 2 diabetic
patients, 18 were positive for a single Ab (14 for GAD and
4 for IA2), and 8 were positive for double antibodies (both
GAD and IA2). There was no difference in insulin-stimu-
lated glucose disposal between 1Ab
 and 2Ab
 groups
(32.8  3.9 vs. 33.3  4.4, NS). First- and second-phase
insulin was higher in the 1Ab
 compared with the 2Ab

patients (314.5  36.1 vs. 165.0  40.0 pmol/l, P  0.02;
482.8  67.1 vs. 239.0  68.6 pmol/l, respectively, P 
0.03). There were no differences in age, BMI, body com-
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FIG. 1. A: Insulin-stimulated total, oxidative, and nonoxidative glucose disposal during the hyperinsulinemic-euglycemic clamp in Ab
 () versus
Ab
 (1) versus control subjects (f). B: Fat oxidation (FOX) during the hyperinsulinemic-euglycemic clamp in the three groups. C: Percent
suppression in fat oxidation during hyperinsulinemia in the three groups. P values by ANOVA. *Post hoc Bonferroni correction; P < 0.05 Ab
 vs.
Ab
,A b
 vs. control subjects.
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level, A1C, and ketonuria at the time of diagnosis.
DISCUSSION
This study was undertaken to determine whether there are
differences in insulin sensitivity and secretion between
Ab
 and Ab
 obese youth with a clinical diagnosis of type
2 diabetes in an effort to shed light on distinguishing
pathophysiological mechanisms. Our results demonstrate
that despite similar body composition and body fat topog-
raphy, 1) youth with Ab
 clinically diagnosed type 2
diabetes have severe impairment in insulin action,
whereas those with Ab
 clinically diagnosed type 2 diabe-
tes have severe impairment in -cell function; 2) youth
with Ab
 type 2 diabetes had additional features consis-
tent with insulin resistance/metabolic syndrome, including
decreased suppression in fat oxidation during hyperinsu-
linemia, higher systolic blood pressure, and higher ALT;
and 3) there were no clinical distinguishing features
between Ab
 and Ab
 youth with clinically diagnosed
type 2 diabetes at the time of diagnosis except for the
higher frequency of ketonuria in the former group.
Between 10 and 75% of youth diagnosed clinically with
type 2 diabetes are reported to have -cell autoantibodies
(10–15). The antibodies tested and reported to be positive
in these patients include ICA in 5–8% (10,12,13,15), GAD in
8–30% (10–12,15), IA-2 in 8–42% (11–13,15), and insulin
antibodies in 5–35% (10–13). In one study, 11% of clinically
diagnosed type 2 diabetic youth were positive for all four
autoantibodies (12). These studies, however, had very
limited numbers of patients from different racial groups
(10–13,15). Some of these studies investigated but could
not ﬁnd clinically distinguishing features between patients
with or without -cell antibodies (10,15). A preliminary
report of a much larger scale of 432 youth with clinically
diagnosed type 2 diabetes screened in TODAY study
revealed that 17.4% were positive for one or both of the
antibodies GAD and IA-2 (14). Ab
 versus Ab
 subjects
did not differ in age, diabetes duration, BMI Z score, and
lipid levels; however, there seemed to be a tendency for
C-peptide to be lower and A1C to be higher in Ab
 youth
(14).
Studies investigating the pathophysiology of youth type
2 diabetes are very limited and have conﬂicting results
(3–6,26). In one of the earliest studies, ﬁrst-phase insulin
response during a frequently sampled intravenous glucose
tolerance test was lower in type 2 diabetic patients com-
pared with obese control subjects with no difference in
insulin sensitivity (3). This was in contrast with another
study where insulin sensitivity was lower (6) in type 2
diabetes. However, despite lower insulin response to
IVGTT, integrated insulin and C-peptide levels during the
OGTT were not different between type 2 diabetic patients
and obese as well as lean control subjects (6). In the
former study, -cell antibodies were not measured, and in
the latter it is not clear which, how many, and how
antibodies were measured. In our previous publication,
GAD and ICA antibodies were measured commercially,
and only type 2 diabetic patients adolescents with negative
antibodies were reported and shown to have 
50% lower
insulin sensitivity and relative insulin deﬁciency (4). In
another study of six adolescents with type 2 diabetes and
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resistance, the impairment in -cell function was highly
variable (5). In another study of 10 obese youth with type
2 diabetes negative for GAD, ICA and IA2, glucose sensi-
tivity of ﬁrst- and second-phase -cell secretion was
signiﬁcantly lower in type 2 diabetic patients compared
with obese youth, whereas insulin sensitivity was similar
between the groups (26). Potential explanations for these
variable ﬁndings could be differences in study population
and ethnicity, differences in diabetes duration and thera-
peutic modalities, differences in methodologies, and dif-
ferences in measuring antibodies. In the present
investigation, we elected to use the same laboratory that
was deemed most appropriate for the NIH-funded multi-
center TODAY study. Our current results suggest that
youth who are clinically diagnosed with type 2 diabetes
but negative for the two tested antibodies have severe
impairment of insulin action, both in glucose and fat
metabolism, which is over and beyond that due to obesity
since there were no differences in total and abdominal
obesity between them and the other two groups. Further-
more, the presence of higher blood pressure and higher
ALT would suggest that this group has an inherent insulin
resistance that is typical of the metabolic syndrome
(27,28). On the other hand, patients clinically diagnosed
with type 2 diabetes but positive antibodies have severe
impairment in -cell function, whereas their insulin action
is signiﬁcantly better than Ab
 patients and near identical
to obese nondiabetic control subjects. This suggests that
the major abnormality is in insulin secretion and not
insulin action, which is typical of autoimmune type 1
diabetes. Thus, it is our proposition that these patients are
merely obese children who happen to develop autoim-
mune type 1 diabetes. Moreover, our limited data would
suggest that there could be a dose-response phenomenon
because ﬁrst- and second-phase insulin secretion in pa-
tients who are positive for double antibodies is 
50%
lower than that of patients who are positive for a single
antibody. Previous limited studies from a single group of
investigators found that some youth clinically classiﬁed
with type 2 diabetes or indeterminant diabetes (admixture
of clinical features of types 1 and 2: type 1.5) show T-cell
reactivity to islet proteins (12) and have type 1 diabetes–
associated HLA alleles (13). Baseline C-peptide levels in
the type 1.5 diabetic patients were signiﬁcantly lower than
those in patients classiﬁed as type 2 diabetic and higher
than those in patients classiﬁed as type 1 diabetic (13). The
ﬁndings in our study provide direct evidence to the more
severe degree of impairment in -cell function in Ab

patients proposed in the aforementioned study. The more
frequent ketonuria at diagnosis in Ab
 patients may be a
reﬂection of the severity of -cell impairment and has been
previously reported (12).
It is not surprising that despite signiﬁcantly more severe
impairment in -cell function in the Ab
 group, there was
no difference in the frequency of insulin treatment be-
tween the two groups of clinically diagnosed type 2
diabetic patients either at diagnosis or at the time of the
study (73% Ab
 vs. 62% Ab
 at diagnosis, and 54% vs. 38%
at the time of the study). Treatment of patients is fre-
quently practitioner driven and not pathophysiology
driven, and these rates of insulin treatment are consistent
with the pediatric literature of type 2 diabetes (29,12,15).
The change in BMI from diagnosis to the time of research
was not different between those patients initially treated
with versus without insulin (data not shown).
Despite these important differences in insulin action and
secretion between Ab
 and Ab
, the GDI, which is insulin
secretion corrected for the degree of insulin sensitivity, is
not different. Our present metabolic observations are
consistent with ﬁndings in GAD
 adults with type 2
diabetes or latent autoimmune diabetes (30). GAD
 adult
patients had decreased early insulin response; however,
when this response was corrected for the degree of insulin
sensitivity, GAD
 and GAD
 patients had similar -cell
function. Thus, in the absence of careful metabolic studies
using sensitive tools, it will be difﬁcult to discern the
underlying pathways: impaired insulin action versus -cell
function, which may result in similar GDI. However, such
knowledge is important to help guide pathophysiology-
based therapy amid the multiple terminologies used: dou-
ble diabetes, hybrid diabetes, diabetes type 1.5, etc.
(8,13,15–18).
In conclusion, important metabolic differences exist in
insulin sensitivity and secretion between obese youth with
versus without evidence of pancreatic autoantibodies.
These metabolic differences highlight different underlying
pathophysiological mechanisms between the two groups
despite a clinical diagnosis of type 2 diabetes. Finally, it
remains to be determined whether the natural history of
diabetes and/or response to treatment and/or micro- and
macrovascular complications differ between Ab
 and Ab

clinically diagnosed obese youth with type 2 diabetes.
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